NeuroPointDX Appoints Noted Neurodevelopmental Expert, Marvin Natowicz, M.D., Ph.D. to its Scientific Advisory Board

Oct. 9, 2018 12:00 UTC

MADISON, Wis.--(BUSINESS WIRE)-- NeuroPointDx today announced the appointment of Marvin Natowicz, M.D., Ph.D., medical geneticist and clinical pathologist at the Cleveland Clinic and Professor of Pathology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

“Dr. Natowicz’s experience as a researcher and a clinician in autism is an important addition to our Scientific Advisory Board,” said Elizabeth Donley, NeuroPointDX Chief Executive Officer. “With his vast knowledge in both genetic and metabolic issues related to autism, he will provide an important perspective as we continue our research in the areas of earlier diagnosis and precise treatments for children with autism.”

Dr. Natowicz’s clinical practice involves the evaluation and care of persons with neurogenetic and neurometabolic conditions, and he has a special interest in working with persons having autism and other developmental disorders. His research interests include studies of genetic and metabolic aspects of autism, the clinical chemistry of genetic metabolic disorders, and public policy issues in genetic medicine. Dr. Natowicz has been on the faculty of Harvard Medical School, the Massachusetts General Hospital and Brandeis University. He obtained his medical degree and doctorate in cellular and developmental biology from Washington University School of Medicine.

About NeuroPointDX and its parent company, Stemina Biomarker Discovery

NeuroPointDX is a division of Stemina Biomarker Discovery, which was founded in 2007 and is located in Madison, Wisconsin. Stemina operates its business in two divisions: NeuroPointDX, focused on diagnosis and more precise treatment of neurological disorders; and Stemina, focused on screening chemicals and compounds for their potential to cause birth defects if a woman is exposed during pregnancy.

Visit NeuroPointDX at

Visit Stemina at



NeuroPointDX & Stemina Biomarker Discovery
Elizabeth Donley, CEO, 608-577-9209
For Media:
Bioscribe, Inc.
Joan Kureczka, 415-821-2413



Source: Stemina Biomarker Discovery

Back to news